Search Result

Results for "

EPACs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Fluorescent Dye (1) Phosphodiesterase (PDE) (2) PKA (7) PKG (1) Ras (10) Virus Protease (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (8) Inflammation/Immunology (1) Metabolic Disease (8) Neurological Disease (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136172

ESI-08 1 Publications Verification	Ras	Cardiovascular Disease Metabolic Disease Cancer
ESI-08 is a potent and selective *EPAC* antagonist, which can completely inhibit both *EPAC1* and *EPAC2* (IC₅₀ of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced *EPAC* activation, but does not inhibit cAMP-mediated PKA activation .

HY-134308

8-NBD-cAMP sodium	Fluorescent Dye	Others
8-NBD-cAMP sodium is a fluorescently labeled cyclic adenosine phosphate (cAMP) analogue. 8-NBD-cAMP sodium retains a similar biological activity to cAMP, regulating their activity by binding to specific proteins such as *EPACs* or PKA. 8-NBD-cAMP sodium can be used in fluorescent competitive binding experiments to evaluate the binding affinity of newly synthesized *EPAC1* agonists to *EPAC1* proteins .

HY-134340

8-pMeOPT-2'-O-Me-cAMP 8-(4-Methoxyphenylthio)-2'-O-Me-cAMP	Others	Others
8-pMeOPT-2'-O-Me-cAMP is an analogue of the signal molecule cAMP and a potent stimulator of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP does .

HY-134332

8-pCPT-5'-AMP 8-(4-Chlorophenylthio)-5'-AMP	PKA PKG	Others
8-pCPT-5'-AMP is an analogue of 5'-AMP and a lipophilic activator of PKA, PKG and *Epac* (exchange protein activated by cAMP) .

HY-134299

8-CPT-cAMP-AM 8-(4-Chlorophenylthio)-cAMP-AM	Others	Others
8-CPT-cAMP-AM is a highly membrane-permeant analogue of signal molecule cAMP. 8-CPT-cAMP-AM is an activator of cAMP- and cGMP-dependent protein kinases and of *Epac* (exchange protein activated by cAMP) .

HY-131766

2'-O-Me-cAMP 2'-O-Methyladenosine-3',5'-cyclic monophosphate	Others	Others
2'-O-Me-cAMP is an analogue of natural signal molecule cAMP and a selective stimulator of the exchange factors activated by cAMP (Epac) with low membrane permeability .

HY-134264

8-Br-2'-O-Me-cAMP	Others	Cardiovascular Disease Neurological Disease
8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research .

HY-131842

6-Bn-cAMP N6-Benzyladenosine-3',5'-cyclic monophosphate	PKA	Cancer
6-Bn-cAMP is a site-selective activator of cAMP-dependent protein kinase (PKA) which does not activate Epac. 6-Bn-cAMP increases hydrolytic stability against PDE, esterases, amidases and considerably higher membrane permeability compared to cAMP .

HY-134263

8-Br-cAMP-AM	PKA Ras	Cardiovascular Disease
8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .

HY-160864

Torbafylline HWA 448	Phosphodiesterase (PDE)	Cancer
Torbafylline is a PDE inhibitor. Torbafylline mitigates protein breakdown in rat skeletal muscle following burns by activating the PDE4/cAMP/EPAC/PI3K/Akt signaling pathway. Torbafylline suppresses the increased ubiquitin-proteasome-dependent protein degradation observed in the skeletal muscles of rats susceptible to cancer and sepsis .

HY-137635

Sp-6-Phe-cAMPS	PKA	Neurological Disease
Sp-6-Phe-cAMPS is a potent, site-selective and membrane-permeable activator of cAMP-dependent protein kinase. Sp-6-Phe-cAMPS does not activate exchange factors directly activated by cAMP and can therefore be used as an Epac negative control. Sp-6-Phe-cAMPS can be used in the study of neurodegenerative diseases .

HY-111446

EPAC 5376753	Ras	Cardiovascular Disease Metabolic Disease Cancer
EPAC 5376753 is an allosterically inhibitor of *Epac* which inhibits Epac1 with an IC₅₀ of 4 µM in Swiss 3T3 cells.

HY-108539

CE3F4 1 Publications Verification	Ras	Cardiovascular Disease
CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC₅₀s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively.

HY-117958

HJC0197 1 Publications Verification	Ras	Cardiovascular Disease Metabolic Disease Cancer
HJC0197 is a potent *Epac1* (exchange protein directly activated by cAMP 1) and *Epac2* (IC₅₀=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 inhibits Epac1-mediated Rap1-GDP exchange activity at 25 μM in the presence of equal concentration of cAMP .

HY-16704

ESI-09 3 Publications Verification	Virus Protease	Cancer
ESI-09 is a novel noncyclic nucleotide *EPAC* antagonist with IC₅₀ values of 3.2 and 1.4 μM for EPAC1 and EPAC2, respectively.

HY-15702

HJC0350 2 Publications Verification	Others	Cancer
HJC0350 is a potent and specific *EPAC2* antagonist with an IC₅₀ of 0.3 µM.

HY-108539A

(R)-CE3F4	Ras	Metabolic Disease
(R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1), with an IC₅₀ of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC₅₀, 44 μM). (R)-CE3F4 is more potent than racemic CE3F4 and (S)-CE3F4 .

HY-117656

ESI-05 3 Publications Verification NSC 116966	Acyltransferase	Neurological Disease Metabolic Disease
ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC₅₀ of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders .

HY-107543

8-CPT-2Me-cAMP sodium	Ras	Others
8-CPT-2Me-cAMP sodium is a selective activator of exchange proteins activated by cAMP (Epac), the cAMP sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2. 8-CPT-2Me-cAMP sodium activates Epac1 (EC₅₀ = 2.2 μM), but not PKA (EC₅₀> 10 μM) . 8-CPT-2Me-cAMP sodium stimulates Epac-mediated Ca ²⁺ release in pancreatic β-cells in vitro .

HY-103322

6-Bnz-cAMP sodium salt	PKA	Cancer
6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways .

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates *Epac-Rap* signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating *Epac* from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway .

HY-129738

I942	Others	Cardiovascular Disease
I942 is a first in class, selective non-cyclic nucleotide (NCN) EPAC1 agonist. I942 can attenuate proinflammatory cytokine signalling normally associated with cardiovascular diseases .

HY-134348

8-pHPT-2'-O-Me-cAMP 8-(4-Hydroxyphenylthio)-2'-O-Me-cAMP	Ras	Cardiovascular Disease
8-pHPT-2'-O-Me-cAMP is a cAMP analog and an *Epac* agonist. 8-pHPT-2'-O-Me-cAMP can be used in cardiac research .

HY-111673

8-CPT-Cyclic AMP sodium 8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC₅₀ of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC₅₀Epac and is a potent *Epac* activator .

HY-137630

Sp-8-pCPT-2'-O-Me-cAMPS	Ras	Metabolic Disease
Sp-8-pCPT-2'-O-Me-cAMPS is an activator of *EPAC*. Sp-8-pCPT-2'-O-Me-cAMPS can be used in endocrine metabolism related research .

HY-137641

Sp-8-Br-2'-O-Me-cAMPS	Ras	Metabolic Disease
Sp-8-Br-2'-O-Me-cAMPS is a cAMP analog. Sp-8-Br-2'-O-Me-cAMPS is an activator of *EPAC*. Sp-8-Br-2'-O-Me-cAMPS can be used in metabolism-related studies .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

EPACs

Inhibitors & Agonists